145 related articles for article (PubMed ID: 26581147)
1. MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.
Gee HE; Buffa FM; Harris AL; Toohey JM; Carroll SL; Cooper CL; Beith J; McNeil C; Carmalt H; Mak C; Warrier S; Holliday A; Selinger C; Beckers R; Kennedy C; Graham P; Swarbrick A; Millar EK; O'Toole SA; Molloy T
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1104-14. PubMed ID: 26581147
[TBL] [Abstract][Full Text] [Related]
2. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
[TBL] [Abstract][Full Text] [Related]
3. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.
Sparano JA; Goldstein LJ; Davidson NE; Sledge GW; Gray R
Breast Cancer Res Treat; 2012 Jul; 134(2):751-7. PubMed ID: 22706628
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
5. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
[TBL] [Abstract][Full Text] [Related]
8. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract][Full Text] [Related]
10. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
11. miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.
Pajic M; Froio D; Daly S; Doculara L; Millar E; Graham PH; Drury A; Steinmann A; de Bock CE; Boulghourjian A; Zaratzian A; Carroll S; Toohey J; O'Toole SA; Harris AL; Buffa FM; Gee HE; Hollway GE; Molloy TJ
Cancer Res; 2018 Jan; 78(2):501-515. PubMed ID: 29180477
[TBL] [Abstract][Full Text] [Related]
12. A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences.
Speers C; Chang SL; Pesch A; Ritter C; Olsen E; Chandler B; Moubadder L; Liu M; Cameron M; Michmerhuizen A; Wilder-Romans K; Zhao SG; Nyati S; Bartelink H; Feng FY; Pierce LJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):686-696. PubMed ID: 32434041
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
Silvestrini R; Veneroni S; Benini E; Daidone MG; Luisi A; Leutner M; Maucione A; Kenda R; Zucali R; Veronesi U
J Natl Cancer Inst; 1997 May; 89(9):639-45. PubMed ID: 9150188
[TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL
Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602
[TBL] [Abstract][Full Text] [Related]
16. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
[TBL] [Abstract][Full Text] [Related]
17. DNA repair gene expression and risk of locoregional relapse in breast cancer patients.
Le Scodan R; Cizeron-Clairac G; Fourme E; Meseure D; Vacher S; Spyratos F; de la Lande B; Cvitkovic F; Lidereau R; Bieche I
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):328-36. PubMed ID: 20092964
[TBL] [Abstract][Full Text] [Related]
18. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of POLQ confers a poor prognosis in early breast cancer patients.
Higgins GS; Harris AL; Prevo R; Helleday T; McKenna WG; Buffa FM
Oncotarget; 2010 Jul; 1(3):175-84. PubMed ID: 20700469
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
